Journal of International Obstetrics and Gynecology ›› 2018, Vol. 45 ›› Issue (3): 327-330.

Previous Articles     Next Articles

Progress of Triptolide in Ovarian Cancer

DU Qiu-yue, SHEN Yan   

  1. Tianjin Central Hospital of Gynecology Obstetrics,Tianjin 300100, China
  • Received:2018-02-23 Revised:2018-05-01 Published:2018-06-15 Online:2018-06-22
  • Contact: SHEN Yan, E-mail: serina_shen@163.com E-mail:yuyanshen29@yahoo.cn

Abstract:  Ovarian cancer is a serious threat to women′s reproductive health, and the mortality is the first of various gynecological tumors. Multidrug resistance(MDR) is a major cause of post-treatment relapses, metastasis, and even death. The role of triptolide(TP) in the treatment of ovarian cancer has attracted much attention, especially in the treatment of MDR in ovarian cancer. In this review, the mechanism of TP on ovarian cancer is reviewed in the two aspects of inhibiting the proliferation and inducing the apoptosis of tumor cells. The toxicity of TP and the short half-life have limited the clinical application. However,the emergence of nano-drug delivery technology has provided  a broader prospect for the treatment of ovarian cancer by TP.

Key words: Triptolide, Ovarian neoplasms, Drug resistance, multiple, Apoptosis, Cell proliferation